Intracranial stents market set to reach $4.9 billion by 2033

By AI, Created 4:25 PM UTC, May 18, 2026, /AGP/ – The global intracranial stents market is projected to grow from $3.4 billion in 2026 to $4.9 billion by 2033, driven by rising cerebrovascular disease, wider use of minimally invasive neurovascular procedures and new stent technologies. North America leads now, while Asia Pacific is expected to post the fastest growth.

Why it matters: - Intracranial stents are becoming more important as cerebrovascular disease rises and hospitals expand minimally invasive treatment options for brain aneurysms, AVMs and intracranial atherosclerosis. - The market’s growth signals more demand for neurovascular devices that can improve recovery times and procedural outcomes.

What happened: - The global intracranial stents market is projected to reach US$3.4 billion in 2026. - The market is forecast to grow at a 5.6% CAGR from 2026 to 2033 and reach US$4.9 billion by 2033. - The market grew at a 5.1% CAGR from 2020 to 2025. - The report was published in London on May 13, 2026. - Persistence Market Research said the market is being driven by rising cerebrovascular disease, minimally invasive neuro-interventions and advanced neurovascular technologies.

The details: - Intracranial stents support cerebral arteries and are used in the management of brain aneurysms, arteriovenous malformations and intracranial atherosclerosis. - Flow-diverter systems and stent-assisted coiling techniques are reshaping treatment practice and reducing recovery periods. - Bioresorbable materials and AI-driven procedural planning are improving long-term safety and procedural efficiency. - The main product segments are balloon-expanding stents, self-expanding stents and stent-assisted coil embolization. - The main disease indications are brain aneurysm, intracranial stenosis, arteriovenous malformations and ischemic stroke. - The main end users are ambulatory surgery centers, hospitals and others. - The report covers North America, Europe, East Asia, South Asia & Oceania, the Middle East & Africa and Latin America. - Download the free sample. - Request customization. - Checkout the full report.

Between the lines: - The market is shifting toward less invasive care, which favors devices that can be deployed through catheter-based procedures instead of open surgery. - High device costs, procedural complexity and reimbursement differences could slow adoption in smaller or resource-constrained hospitals. - The market is moderately consolidated, with Medtronic, Stryker and Terumo Neuro holding strong positions through global distribution and integrated neurovascular platforms. - Companies are competing on material innovation, low-profile designs and anti-thrombogenic coatings. - Medtronic’s acquisition of Scientia Vascular and Stryker’s purchase of Inari Medical point to a broader push to build out neurovascular portfolios. - Government programs in the U.S. and China are supporting stroke prevention, rapid intervention, specialized centers and neuro-interventional training. - FDA Breakthrough Device Designations, including MicroPort’s APOLLO Dream® Sirolimus Stent, are helping speed access to advanced stent technologies.

What’s next: - North America is expected to lead with a 35% market share in 2026, supported by stroke care infrastructure, higher healthcare spending and reimbursement support. - Europe is expected to remain a mature market, with demand shaped by replacement cycles and MDR regulatory standards. - Asia Pacific is expected to be the fastest-growing region as infrastructure expands and China scales domestic manufacturing and training programs. - Continued work on AI-assisted planning, hybrid therapy and bioresorbable stents is likely to shape the next wave of product development.

The bottom line: - The intracranial stents market is on track for steady growth through 2033, with innovation and broader clinical adoption offsetting cost and training barriers.